FURFARO, ELISA
 Distribuzione geografica
Continente #
EU - Europa 3.539
AS - Asia 17
Totale 3.556
Nazione #
IT - Italia 3.539
CN - Cina 16
SG - Singapore 1
Totale 3.556
Città #
Genova 2.142
Genoa 846
Rapallo 308
Vado Ligure 237
Beijing 6
Bordighera 6
Singapore 1
Totale 3.546
Nome #
Initial serum (1,3)-β-d-glucan as a predictor of mortality in proven candidaemia: findings from a retrospective study in two teaching hospitals in Italy and Brazil 197
Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. 160
Non-cultural methods for the diagnosis of invasive fungal disease 156
Is initial serum (1,3)-β-d-glucan truly associated with mortality in patients with candidaemia? Authors' response 151
Biomarkers for Diagnosis and Follow-Up of Invasive Candidiasis: A Brief Review of the ECIL Recommendations 150
Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia 146
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 146
Galactomannan in piperacillin-tazobactam: how much and to what extent? 143
Invasive mycoses in children receiving hemopoietic SCT 143
Lower sensitivity of serum (1,3)-β-D-glucan for the diagnosis of candidaemia due to Candida parapsilosis 141
(1-3)-β-d-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. 140
Galactomannan: testing the same sample twice? 138
High levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease 135
Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible forfalse-positive results of the galactomannan assay 130
Screening With Serum Galactomannan Might Be Associated With Better Outcome Than Symptom-Triggered Galactomannan Testing in Allogeneic HSCT Recipients With Invasive Aspergillosis. 127
The Beta-d-glucan Test: Time to Re-Visit Its Utility in IFI Diagnosis 127
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. 126
Combined use of serum (1,3)-β-d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units 121
Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation 120
Galactomannan testing might be useful for early diagnosis of fusariosis. 119
Aspergillus meningitis: A rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. 117
Performance of 1,3-β-D-glucan for diagnosing invasive fungal diseases in children 117
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy 98
Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients 96
Case report of the reliability 1,3-β-D-glucan monitoring during treatment of peritoneal candidiasis in a child receiving continuous peritoneal dialysis 88
Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients. 84
Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan 81
Levels of beta-D-glucan in Candida auris supernatants, an in vitro and in vivo preliminary study 55
Bloodstream infections are an improbable cause of positive serum (1,3)-β-D-glucan in hematology patients 48
The Importance of Quantitative Results of a Lateral Flow Aspergillus Assay: The Significant Impact on Specificity 10
Totale 3.610
Categoria #
all - tutte 12.210
article - articoli 12.210
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.420


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021227 0 0 0 26 15 20 15 62 17 37 14 21
2021/2022343 6 16 16 48 18 45 17 74 15 38 8 42
2022/2023369 35 38 7 35 64 65 1 25 56 4 28 11
2023/2024192 10 21 4 30 18 32 11 8 9 2 23 24
2024/2025582 6 38 12 37 92 60 46 100 17 23 56 95
2025/2026273 151 20 49 53 0 0 0 0 0 0 0 0
Totale 3.610